Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. NASDAQ:BOLT, a clinical-stage biotechnology company advancing next-generation, half-life-extended multispecific antibodies, today reported financial results for the third quarter ended September 30, 2026, and provide…